Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials

Documents similaires

• The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management
  par: Sima Fansa, et autres
  Publié: (2024)
• Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
  par: Matthew J. Armstrong, et autres
  Publié: (2024)
• Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
  par: Masashi Hasebe, et autres
  Publié: (2025)
• Association between glycated haemoglobin A 1c and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof‐of‐concept study
  par: Janis Schierbauer, et autres
  Publié: (2025)
• Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
  par: Gregor A. Maier, et autres
  Publié: (2026)